Premium
Daylight photodynamic therapy with methylene blue in plane warts: a randomized double‐blind placebo‐controlled study
Author(s) -
Fathy Ghada,
Asaad Marwa Kamal,
Rasheed Haval Mohamad
Publication year - 2017
Publication title -
photodermatology, photoimmunology and photomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.736
H-Index - 60
eISSN - 1600-0781
pISSN - 0905-4383
DOI - 10.1111/phpp.12291
Subject(s) - photodynamic therapy , medicine , placebo , methylene blue , daylight , photosensitizer , dermatology , surgery , pathology , photochemistry , optics , biochemistry , chemistry , physics , alternative medicine , organic chemistry , photocatalysis , catalysis
Summary Background Conventional photodynamic therapy is associated with inconveniently long clinic visits and discomfort during therapy. Daylight‐photodynamic therapy ( DL ‐ PDT ) is an effective treatment, nearly pain free and more convenient for both the clinics and patients. There are no published studies of methylene blue ( MB ) as a photosensitizer ( PS ) used in DL ‐ PDT . Methods Forty patients had multiple plane warts; 20 patients were subjected to DL ‐ PDT with topical 10% methylene blue gel, and 20 patients were subjected to DL ‐ PDT with hematoxylin (placebo). Improvement was evaluated by change of the number of warts and the dermoscope picture. Results A total of 20 (100%) patients in group II showed no response to placebo, 13 patients (65%) in group I showed complete clearance, 2 (10%) patients showed a good response, and 5 (25%) patients had poor response to treatment ( P < 0.01). No serious side effects and patients tolerated the pain well. No relapse was detected during the follow‐up period (12 months). Limitation of the study Daylight exposure was not monitored with a dosimeter. Conclusion Daylight‐ PDT using MB is safe, easy to carry out, economic, effective, acceptable cosmetic results with no recurrence, convenient especially for children and nearly painless treatment.